We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

5 hedge funds and large institutions have $405K invested in XTL Biopharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding

Funds holding: 4 → 5 (+1)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

16% less capital invested

Capital invested by funds: $483K → $405K (-$77.8K)

Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BRWA
B. Riley Wealth Advisors
Florida
+$1.32K
2
TRCT
Tower Research Capital (TRC)
New York
+$794

Top Sellers

Rank Fund Capital Flow
1
U
UBS
Switzerland
-$1.32K
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
1
Invesco
Georgia
$397K – – –
U
2
UBS
Switzerland
$4K -$1.32K -20 -24%
TRCT
3
Tower Research Capital (TRC)
New York
$2K +$794 +12 +48%
BRWA
4
B. Riley Wealth Advisors
Florida
$1.22K +$1.32K +20 New
Ameriprise
5
Ameriprise
Minnesota
$1K – – –

XTLB Hedge Fund Activity: Q2 2014 in Review

5 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q2 2014, worth a combined $405K — down 16% from $483K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new XTLB positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was B. Riley Wealth Advisors, opening a new position worth an estimated $1.32K. The largest seller was UBS, cutting an estimated $1.32K.

  • 5 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q2 2014, up from 4 in Q1 2014.
  • Funds reported $405K of XTL Biopharmaceuticals stock for Q2 2014, down 16% quarter-over-quarter.
  • 1 fund opened new XTL Biopharmaceuticals positions in Q2 2014 and 0 closed out, a net change of +1 holder.
  • The largest XTL Biopharmaceuticals buyer in Q2 2014 was B. Riley Wealth Advisors, an estimated $1.32K added.
  • The largest XTL Biopharmaceuticals seller in Q2 2014 was UBS, an estimated $1.32K sold.

Based on aggregated 13F filings for Q2 2014.